Overview of Glp 1 Receptor Agonists Molecule Of The Month

GLP-1 receptor agonists got their start in an unlikely place: the mouth of a lizard. A peptide that was discovered in Gila monster saliva, called exendin-4, was found to mimic the action of GLP-1 and was developed into the drug exenatide (sold under the name Byetta) for the treatment of type 2 diabetes. Exenatide (shown on the right, PDB 7LLL), which was the first GLP-1 receptor agonist ...

This is an mirror page of the " Molecule of the Month " article provided in PDB-101 of the RCSB PDB. This article was released on November 2025. To reprinting and citation, please refer our terms and conditions page.
Key Details About Glp 1 Receptor Agonists Molecule Of The Month

Many GPCRs, including GLP -1R and GIPR, couple to the stimulatory G protein, Gs, to activate adenylyl cyclase and produce the second messenger cyclic AMP. You can read more about G proteins in a previous Molecule of the Month article. On the left, GLP-1 binds to the GLP-1 receptor , which itself is bound to a trimeric G protein (PDB 6B3J).
Glucagon-like peptide-1 receptor ( GLP -1R) agonists are injectable peptide-based therapies that have become a focal point in the medical community due to their significant therapeutic efficacy in type 2 diabetes and obesity treatment. Recent advancements in medicinal chemistry have enabled the development of small- molecule GLP -1R agonists , presenting advantages such as oral administration ...

Useful Notes on Glp 1 Receptor Agonists Molecule Of The Month
Glucagon-like peptide-1 ( GLP-1 ) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ago...
This review provides a comprehensive and scholarly examination of glucagon-like peptide-1 receptor ( GLP -1R) agonists , tracing their evolution from glycemic control agents in diabetes mellitus (DM) to multifaceted therapeutics with expanding ...

Emerging Frontiers in GLP
Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) have evolved from glucose-lowering agents to transformative therapies across multiple organ systems. This comprehensive review synthesizes current evidence on the mechanisms, established ...
Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake. 5 Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018.

Key Details About Glp 1 Receptor Agonists Molecule Of The Month
Additionally, this paper explores the potential applications of GLP-1 receptor agonists ( GLP -1RAs) in fields such as neuroprotection, anti-infection measures, the reduction of various types of ...








GLP-1 receptor activation slows gastric emptying, inhibits the release of glucagon, and stimulates insulin production, thereby improving glucose homeostasis in people with type 2 diabetes. At the cellular level, binding to the GLP-1 receptor on pancreatic beta cells elevates intracellular cyclic AMP (cAMP) and activates protein kinase A (PKA). This cascade triggers the influx of calcium, which ...